Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 781 to 795 of 1516 results for patients and public

  1. Irbesartan–propagermanium for treating focal segmental glomerulosclerosis in people 12 years and over having an angiotensin II receptor blocker [ID6469]

    Awaiting development Reference number: GID-TA11575 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Subcutaneous efgartigmod with recombinant human hyaluronidase PH20 for treating primary immune thrombocytopenia [TSID11977]

    Awaiting development Reference number: GID-TA11507 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Brentuximab vedotin with etoposide, cyclophosphamide, doxorubicin, dacarbazine and dexamethasone for untreated advanced classical Hodgkin lymphoma [ID6437]

    Awaiting development Reference number: GID-TA11516 Expected publication date:  06 May 2027

    Technology appraisal guidance
    Awaiting development

  4. Dupilumab for treating eosinophilic oesophagitis in children 1 to 11 years [ID6492]

    Awaiting development Reference number: GID-TA11383 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Opicapone for adjunctive treatment of motor signs and symptoms in Parkinson's disease TS ID 11941

    Awaiting development Reference number: GID-TA11481 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Xeomin (botulinum neurotoxin type A) for treating lower limb spasticity [TSID11902]

    Awaiting development Reference number: GID-TA11417 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Troriluzole for spinocerebellar ataxia [ID6456]

    Awaiting development Reference number: GID-TA11549 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Tiragolumab–atezolizumab for PD-L1-positive recurrent or advanced non-small-cell lung cancer untreated with checkpoint inhibitors [TSID12064]

    Awaiting development Reference number: GID-TA11594 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Alpha-1 antitrypsin for treating high-risk acute graft-versus-host disease after a haematopoietic stem cell transplant in people 12 years and over [TSID12036]

    Awaiting development Reference number: GID-TA11596 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Upadacitinib for treating moderate to severe hidradenitis suppurativa in people 12 years and over [ID6666]

    Awaiting development Reference number: GID-TA11825 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Niraparib with abiraterone acetate and prednisone for treating hormone-sensitive metastatic prostate cancer [ID6595]

    Awaiting development Reference number: GID-TA11558 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Sacituzumab govitecan with pembrolizumab for untreated metastatic non-small-cell lung cancer with a PD-L1 expression of 50% or more [TSID12280]

    Awaiting development Reference number: GID-TA11880 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Imsamotide with etimumotide and pembrolizumab for untreated unresectable or metastatic melanoma in people 12 years and over [TSID12279]

    Awaiting development Reference number: GID-TA11882 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Vamikibart for treating uveitic macular oedema [ID6671]

    Awaiting development Reference number: GID-TA11885 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. V940 with pembrolizumab for adjuvant treatment of resected high-risk stage 2 to 4 melanoma [ID6674]

    Awaiting development Reference number: GID-TA11881 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development